UPDATED: Investors to Hear From Corvas International, Inc. Along With Keynote Speaker Robert Winslow At November 5th Informed Investors Biotechnology/Healthcare Stocks Forum.Business Editors/Hi-Tech Writers RICHMOND, Va.--(BUSINESS WIRE)--Nov. 1, 2002 Investors interested in tracking biotechnology stocks can gather insights as Corvas International Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CVAS) presents at the Biotechnology/Healthcare Stocks Forum along with other biotech companies. Dr. Robert Winslow founder of Sangart, Inc. and an expert in biotechnology with over 30 years experience will present the Keynote. This free online Forum, gives investors the opportunity to hear directly from company executives to get their investment information straight from the source. The presentations will be accessible live at www.informedinvestors.com from 9:00 a.m.-11:00 a.m. EST EST electroshock therapy. EST abbr. electroshock therapy Tuesday, November 5. As part of the forum, Investors are invited to email questions to the executives. The forum will also be archived and available afterwards on www.informedinvestors.com, www.vcall.com and www.investorconference.com. Corvas International Inc., is a biopharmaceutical company focused on the discovery and development of novel therapeutics that address today's largest medical markets, cardiovascular disease and cancer, based on the Company's expertise in vascular biology and protease modulation. Corvas expects to initiate a Phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II in unstable angina and non-ST-segment elevation myocardial infarction patients in the fourth quarter of 2002 with its novel anticoagulant rNAPc2. The Company's cancer program is based on an enzyme family, genomics-driven approach to the discovery of therapeutic products that modulate the activity of serine proteases associated with the growth and progression of solid tumors. Professor Winslow received his M.D. degree and postgraduate training in internal medicine and hematology at the Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. and Hospital. He studied hemoglobin biochemistry at the Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, and molecular biology at the National Institutes of Health. His research, for more than 30 years, has been aimed at the intersection of the synthesis, structure and function of hemoglobin, in such areas as sickle cell anemia sickle cell anemia n. A chronic, usually fatal inherited form of anemia marked by crescent-shaped red blood cells, occurring almost exclusively in Blacks, and characterized by fever, leg ulcers, jaundice, and episodic pain in the joints. , high altitude physiology and, most recently, hemoglobin-based oxygen carriers. Professor Winslow previously headed the Blood Research Division at the Letterman Army Institute of Research, responsible for the US Army's blood substitute program. Between 1991 and 1998, he was a Professor of Medicine, leading a blood substitute program at the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). at San Diego (UCSD), supported by the National Institutes of Health. Professor Winslow has also served as a consultant to many private companies and has been an advisor for, among others, the Federal Aviation Administration Federal Aviation Administration (FAA), component of the U.S. Department of Transportation that sets standards for the air-worthiness of all civilian aircraft, inspects and licenses them, and regulates civilian and military air traffic through its air traffic control (FAA), Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ), the Institute of Medicine of the National Academy of Science, the Pan American Health Organization The Pan American Health Organization (PAHO) is an international public health agency with 100 years of experience in working to improve health and living standards of the countries of the Americas. It serves as the specialized organization for health of the Inter-American System. , the National Institutes of Health, the Department of Defense and a number of foreign governments. He has written more than 180 scientific articles on clinical, physiological and biochemical aspects of hemoglobin and oxygen transport. In addition to these medical and scientific qualifications, Professor Winslow served on the Board of Directors of a financial services Institution based in Minneapolis, Minnesota. Professor Winslow is the president and chairman of the board of Sangart. http://www.Sangart.com Informed Investors is the leading producer of online and offline industry-specific investment conferences for individual investors and a member of the WILink suite of PrecisionIR(TM) services serving publicly traded companies and self-reliant investors. About WILink Since 1992, WILink plc (www.wilink.com) has been a leading provider of global investor relations and investment information services that attract and retain investors for public companies and mutual funds. WILink's PrecisionIR(TM) (www.precisionir.com) and PrecisionFM(TM) custom investor-marketing programs enable publicly traded companies and mutual funds to deliver tailored and compelling communications to a precisely targeted audience of investors. This year WILink will make more than 7 million investor introductions for over 4,200 corporate clients through PrecisionIR(TM) and PrecisionFM(TM) programs, which include the Annual Reports Service, the Fund Info Service, Informed Investors Forums (www.informedinvestors.com) and Vcall(R) webcasting (www.vcall.com). WILink's InstitutionalReach(TM) database and partnerships with over 230 leading financial channels in 14 countries including The Wall Street Journal, Financial Times, Barron's and Yahoo! Finance ensure clients targeted visibility within the investment community. WILink, Inc. a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of WILink plc (WLK:LSE LSE - Language Sensitive Editor ) began operations in Richmond, Va. in 1993. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion